Abstract:Background Nosocomial bloodstream infections (nBSI) have emerged as a clinical concern for physicians treating COVID-19 patients. In this study, we aimed to evaluate the effectiveness of a multiplex ddPCR in detecting bacterial pathogens in the blood of COVID-19 critically ill patients. Methods This prospective diagnostic study included RT-PCR-confirmed COVID-19 patients admitted to our hospital from December 2022 to February 2023. A multiplex ddPCR assay was used to detect common bacterial pathogens and AMR genes in blood samples of the patients, along with antimicrobial susceptibility testing (AST). The diagnostic performance of the ddPCR assay was evaluated by comparing the results with those obtained through blood culture and clinical diagnosis. Additionally, the ability of ddPCR in detecting bacterial resistance was compared with the AST results. Results Of the 200 blood samples collected from 184 patients, 45 (22.5%) were positive using blood culture, while 113 (56.5%) were positive for bacterial targets using the ddPCR assay. The ddPCR assay outperformed blood culture in pathogen detection rate, mixed infection detection rate, and fungal detection rate. Acinetobacter baumannii and Klebsiella pneumoniae were the most commonly detected pathogens in COVID-19 critically ill patients, followed by Enterococcus and Streptococcus . Compared to blood culture, ddPCR achieved a sensitivity of 75.5%, specificity of 51.0%, PPV of 30.9%, and NPV of 87.8%, respectively. However, there were significant differences in sensitivity among different bacterial species, where Gram-negative bacteria have the highest sensitivity of 90.3%. When evaluated on the ground of clinical diagnosis, the sensitivity, specificity, PPV and NPV of ddPCR were 78.1%, 90.5%, 94.7%, and 65.5%, respectively. In addition, the ddPCR assay detected 23 cases of bla KPC , which shown a better consistent with clinical test results than other detected AMR genes. Compared to bla KPC , there were few other AMR genes detected, indicating that the application of other AMR gene detection in the COVID-19 critically ill patients was limited. Conclusion The multiplex ddPCR assay had a significantly higher pathogen detection positivity than the blood culture, which could be an effective diagnostic tool for BSIs in COVID-19 patients and to improve patient outcomes and reduce the burden of sepsis on the healthcare system, though there is room for optimization of the panels used.- Adjusting the targets to include E. faecalis and E. faecium as well as Candida albicans and Candida glabrata could improve the ddPCR' s effectiveness. However, further research is needed to explore the potential of ddPCR in predicting bacterial resistance through AMR gene detection.

Clinical Performance of BALF Droplet Digital PCR for Differential Diagnosis of Pneumocystis jirovecii Pneumonia and Pneumocystis jirovecii Colonization

Relationship between clinical features and droplet digital PCR copy number in non-HIV patients with pneumocystis pneumonia

Development of a Droplet Digital Polymerase Chain Reaction for Sensitive Detection of <i>Pneumocystis jirovecii</i> in Respiratory Tract Specimens

Quantitative real time PCR for distinction between Pneumocystis jirovecii infection/colonization in hospitalized patients

Clinical Performance of BAL Metagenomic Next-Generation Sequence and Serum (1,3)-β-D-Glucan for Differential Diagnosis of Pneumocystis jirovecii Pneumonia and Pneumocystis jirovecii Colonisation

Evaluation of PCR in Bronchoalveolar Lavage Fluid for Diagnosis of Pneumocystis Jirovecii Pneumonia: A Bivariate Meta-Analysis and Systematic Review

Determining Pneumocystis jirovecii Colonisation from Infection Using PCR-Based Diagnostics in HIV-Negative Individuals

Diagnostic Value of Fluorescence Real-Time PCR for Pneumocystis Pneumonia in AIDS Patients

Diagnostic values of BALF metagenomic next-generation sequencing, BALF real-time PCR and serum BDG for Pneumocystis jirovecii pneumonia in HIV-infected patients

The Application of Nanopore Targeted Sequencing for Pathogen Diagnosis in Bronchoalveolar Lavage Fluid of Patients with Pneumonia: a Prospective Multicenter Study.

-D-Glucan for Differential Diagnosis of Pneumocystis jirovecii Pneumonia and Pneumocystis jirovecii Colonisation</p>

Polymerase Chain Reaction on Respiratory Tract Specimens of Immunocompromised Patients to Diagnose Pneumocystis Pneumonia: A Systematic Review and Meta-analysis

Detection of Pneumocystis Jirovecii and Toxoplasma Gondii in Patients with Lung Infections by a Duplex Qpcr Assay.

[Epidemiological Characteristics of Pneumocystis Jirovecii Infection and Colonization in Non-Aids Patients].

Absolute Quantification of Mycoplasma Pneumoniae in Infected Patients by Droplet Digital PCR to Track Disease Severity and Treatment Efficacy

Analytical and clinical validation of multiplex droplet digital PCR assay for detecting pathogenic fungal infection in lungs

Cellular analysis and metagenomic next-generation sequencing of bronchoalveolar lavage fluid in the distinction between pulmonary non-infectious and infectious disease

Detection of Mycoplasma pneumoniae in different respiratory specimens

B-204 A Real-time Probe-based PCR Assay for Detection of Pneumocystis Pneumonia

Interpretation of results of PCR and B-D-glucan for the diagnosis of Pneumocystis Jirovecii Pneumonia in immunocompromised adults with acute respiratory failure

Clinical evaluation of a multiplex droplet digital PCR for pathogen detection in critically ill COVID-19 patients with bloodstream infections